- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05364762
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
Single Center Pilot Study to Investigate the Efficacy of Adding Itacitinib to Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning Matched Donor Hematopoietic Cell Transplantation With Peripheral Blood Stem Cells as Graft Source
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. Safety lead-in: Determine if shortening tacrolimus administration period to 60 days (day +65 post-hematopoietic cell transplantation [HCT]), when combined with post-transplant cyclophosphamide (PTCy) and itacitinib at a fixed dose level as graft-versus-host disease (GVHD) prophylaxis, is safe and effective after mobilized peripheral blood stem cell (PBSC) allogeneic hematopoietic cell transplantation (HCT) from a matched related/unrelated donor, as assessed by grade 3-4 GVHD as dose limiting toxicity.
II. Following the safety lead-in, evaluate the efficacy of PTCy, itacitinib and tacrolimus GVHD prophylaxis, as assessed by 1-year GVHD-free relapse-free survival (GRFS).
SECONDARY OBJECTIVES:
I. Evaluate the safety of this regimen by assessing:
Ia. Adverse events: type, frequency, severity, attribution, time course, duration.
Ib. Complications including acute and chronic GVHD, infections and delayed engraftment.
II. Estimate overall survival (OS), progression-free survival (PFS), cumulative incidences of relapse/disease progression, and non-relapse mortality (NRM) at 100 days, and 1-year post-transplant.
III. Estimate rates of acute and chronic GvHD, infections, and neutrophil recovery.
EXPLORATORY OBJECTIVES:
I. Donor cell engraftment will be assessed by count monitoring and short tandem repeat (STR) chimerism analysis on days +30 and day +100.
II. Describe the kinetics of immune cell recovery. III. Evaluate patient's quality of life on day +100, 6 months and one-year post-HCT.
IV. Pharmacokinetics: serial blood sampling will be done to evaluate the steady-state pharmacokinetics of itacitinib after PTCy.
V. Describe the kinetics of GVHD biomarkers, JAK-related inflammatory cytokines and STAT phosphorylation.
VI. Evaluate and describe the cytokine release syndrome (CRS) post-HCT by assessing the incidence, frequency, and severity of CRS.
VII. Obtain a preliminary estimate of gut microbiome diversity at baseline (preferably before fludarabine administration), and then on days +14, +30, and +100.
OUTLINE:
Patients undergo peripheral blood stem cell infusion on day 0. Patients receive cyclophosphamide intravenously (IV) once daily (QD) on days 3 and 4, itacitinib orally (PO) QD on days 5-100, and tacrolimus IV or PO on days 6-65.
After completion of study treatment, patients are followed up at day 180 and 1 year.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Medical Center
-
Contact:
- Monzr M. Al Malki
- Phone Number: 626-218-2405
- Email: malmaki@coh.org
-
Principal Investigator:
- Monzr M. Al Malki
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Documented informed consent of the participant and/or legally authorized representative
- Assent, when appropriate, will be obtained per institutional guidelines
Agreement to allow the use of archival tissue from diagnostic tumor biopsies
- If unavailable, exceptions may be granted with study principal investigator (PI) approval
Age: =< 80 years
- Note: Patients > 70 years of age must have Karnofsky performance status >= 80 and HCT-comorbidity index (CI) =< 2
- Karnofsky performance status >= 70%
Patients with the following diagnosis, eligible to undergo allogeneic HCT from an 8/8 match related/unrelated donor (A, B, C, DR by high resolution typing)
- Acute leukemias (acute myeloid leukemia [AML] or acute lymphoblastic leukemia [ALL]) in complete remission with bone marrow (BM) blast of < 5%
- Myelofibrosis (MF): Primary or secondary with high- or intermediate-2 risk per Dynamic International Prognostic Scoring System (DIPSS)
- Myelodysplastic syndrome (blast < 10%)
- Myeloproliferative neoplasm (MPN) other than MF needing HCT
- Chronic myelomonocytic leukemia (CMML)
- Total bilirubin =< 2 x upper limit of normal (ULN) (unless has Gilbert's disease) (within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- Serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) < 5 x ULN (within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- Creatinine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (within 30 days prior to day 1 of protocol therapy unless otherwise stated)
Left ventricular ejection fraction (LVEF) >= 50%
- Note: To be performed within 30 days prior to day 1 of protocol therapy
- If able to perform pulmonary function tests: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lungs for carbon monoxide (DLCO) (diffusion capacity) >= 50% of predicted (corrected for hemoglobin) (within 30 days prior to day 1 of protocol therapy)
- If unable to perform pulmonary function tests: O2 saturation > 92% on room air (within 30 days prior to day 1 of protocol therapy)
Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis rapid plasma reagin (RPR) (within 30 days prior to day 1 of protocol therapy)
- If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed OR
- If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable
Meets other institutional and federal requirements for infectious disease titer requirements
- Note: Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (within 30 days prior to day 1 of protocol therapy)
- If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy
- Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
Exclusion Criteria:
- Prior allogeneic HCT
Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy
- Note: Conditioning regimen within 21 days prior to day 1 of protocol therapy is not considered as an exclusion criterion. Patients on maintenance chemotherapy are not excluded
- Other investigational drugs for treatment of GVHD
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents
- Psychological issues, no appropriate caregivers identified, or non-compliant to medication
- Clinically significant uncontrolled illness
- Uncontrolled infection (bacterial, viral, fungal)
- Other active malignancy
- Females only: Pregnant or breastfeeding
- Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prevention (PBSCs, cyclophosphamide, itacitinib, tacrolimus)
Patients undergo peripheral blood stem cell infusion on day 0. Patients receive cyclophosphamide IV QD on days 3 and 4, itacitinib PO QD on days 5-100, and tacrolimus IV or PO on days 6-65.
|
Ancillary studies
Other Names:
Given IV
Other Names:
Given IV or PO
Other Names:
Given PO
Other Names:
Undergo peripheral blood stem cell infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Grade III-IV acute graft versus host disease (GVHD)
Time Frame: By day 100
|
Acute GVHD will be graded and staged according to Mount Sinai Acute GVHD International Consortium (MAGIC) criteria.
|
By day 100
|
GVHD-free relapse-free survival rate
Time Frame: From start of hematopoietic cell transplantation to grade III-IV acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed at 1 year
|
Will be calculated using the Kaplan-Meier method.
|
From start of hematopoietic cell transplantation to grade III-IV acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed at 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 2 years
|
The toxicity/adverse event information recorded on each subject will include type, severity, duration, and attribution/ association with the study regimen.
Tables will be constructed to summarize the observed incidence, severity and type of toxicity, including infection.
|
Up to 2 years
|
Overall survival
Time Frame: Day of stem cell infusion (day 0) until death or last follow-up, assessed at 100 days
|
Will be calculated using the Kaplan-Meier method.
|
Day of stem cell infusion (day 0) until death or last follow-up, assessed at 100 days
|
Overall survival
Time Frame: Day of stem cell infusion (day 0) until death or last follow-up, assessed at 180 days
|
Will be calculated using the Kaplan-Meier method.
|
Day of stem cell infusion (day 0) until death or last follow-up, assessed at 180 days
|
Overall survival
Time Frame: Day of stem cell infusion (day 0) until death or last follow-up, assessed at 1 year
|
Will be calculated using the Kaplan-Meier method.
|
Day of stem cell infusion (day 0) until death or last follow-up, assessed at 1 year
|
Progression free survival
Time Frame: From the date of stem cell infusion to the date of death, disease relapse/progression, or last follow-up, assessed at 100 days
|
Will be calculated using the Kaplan-Meier method.
|
From the date of stem cell infusion to the date of death, disease relapse/progression, or last follow-up, assessed at 100 days
|
Progression free survival
Time Frame: From the date of stem cell infusion to the date of death, disease relapse/progression, or last follow-up, assessed at 180 days
|
Will be calculated using the Kaplan-Meier method.
|
From the date of stem cell infusion to the date of death, disease relapse/progression, or last follow-up, assessed at 180 days
|
Progression free survival
Time Frame: From the date of stem cell infusion to the date of death, disease relapse/progression, or last follow-up, assessed at 1 year
|
Will be calculated using the Kaplan-Meier method.
|
From the date of stem cell infusion to the date of death, disease relapse/progression, or last follow-up, assessed at 1 year
|
Relapse/progression
Time Frame: Day 0 to relapse/progression, assessed at 100 days
|
The cumulative incidence will be calculated using the competing risk method.
|
Day 0 to relapse/progression, assessed at 100 days
|
Relapse/progression
Time Frame: Day 0 to relapse/progression, assessed at 180 days
|
The cumulative incidence will be calculated using the competing risk method.
|
Day 0 to relapse/progression, assessed at 180 days
|
Relapse/progression
Time Frame: Day 0 to relapse/progression, assessed at 1 year
|
The cumulative incidence will be calculated using the competing risk method.
|
Day 0 to relapse/progression, assessed at 1 year
|
Non-relapse mortality
Time Frame: Day 0 until non-disease related death or last follow-up, assessed at 100 days
|
The cumulative incidence will be calculated using the competing risk method.
|
Day 0 until non-disease related death or last follow-up, assessed at 100 days
|
Non-relapse mortality
Time Frame: Day 0 until non-disease related death or last follow-up, assessed at 180 days
|
The cumulative incidence will be calculated using the competing risk method.
|
Day 0 until non-disease related death or last follow-up, assessed at 180 days
|
Non-relapse mortality
Time Frame: Day 0 until non-disease related death or last follow-up, assessed at 1 year
|
The cumulative incidence will be calculated using the competing risk method.
|
Day 0 until non-disease related death or last follow-up, assessed at 1 year
|
Rate of acute GVHD
Time Frame: On day 100
|
Acute GVHD will be graded and staged according to MAGIC criteria.
The first day of acute GVHD onset at a certain grade will be used to calculate the cumulative incidence (grades II-IV).
The endpoint will be evaluated from day 0 through 100 days post-transplant.
The cumulative incidence will be calculated using the competing risk method.
|
On day 100
|
Rate of chronic GVHD
Time Frame: From day 80 through 1 year post-transplant
|
Chronic graft versus host disease will be evaluated and scored according to National Institutes of Health Consensus Staging.
The first day of chronic GVHD onset will be used to calculate the cumulative incidence.
The cumulative incidence will be calculated using the competing risk method.
|
From day 80 through 1 year post-transplant
|
Rate of infection
Time Frame: Day -7 to day 120
|
Microbiologically documented infections will be reported by site of disease, date of onset, severity and resolution, if any.
This data will be captured via case report form and will be collected from day -7 to day 120 post-transplant and will follow the same data collection intervals as the toxicity and adverse event data.
|
Day -7 to day 120
|
Rate of hematologic recovery
Time Frame: Up to 2 years
|
Absolute neutrophil count >= 0.5 x 10^3/uL achieved and sustained for 3 consecutive lab values on different days with no subsequent decline. Platelets >= 20 K/uL independent of platelet transfusion support (date should reflect no transfusions in previous 7 days, and the first of 3 consecutive lab values on different days). |
Up to 2 years
|
Incidence of cytokine release syndrome
Time Frame: Up to 2 years
|
Defined and graded per American Society for Transplantation and Cellular Therapy criteria.
|
Up to 2 years
|
Gut microbiome assessment
Time Frame: Up to 2 years
|
Gut microbiome diversity will be assessed by the inverse Simpson Index and compared among CBM588-treated/untreated patients; the inverse Simpson index is an ecological measure of α microbial diversity calculated by the inverse of the expected probability of 2 randomly selected bacterial sequences as belonging to the same operational taxonomic unit.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Monzr M Al Malki, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myelodysplastic-Myeloproliferative Diseases
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Chronic Disease
- Myelodysplastic Syndromes
- Primary Myelofibrosis
- Leukemia
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Myeloproliferative Disorders
- Graft vs Host Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Calcineurin Inhibitors
- Cyclophosphamide
- Tacrolimus
Other Study ID Numbers
- 21776 (Other Identifier: City of Hope Medical Center)
- P30CA033572 (U.S. NIH Grant/Contract)
- NCI-2022-03765 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States